RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Editas Medicine P/E 2024

Editas Medicine P/E

-1.84

Editas Medicine Dividend yield

Ticker

EDIT

ISIN

US28106W1036

WKN

A2AC4K

As of Apr 30, 2024, Editas Medicine's P/E ratio was -1.84, a -61.1% change from the -4.73 P/E ratio recorded in the previous year.

The Editas Medicine P/E history

Editas Medicine Aktienanalyse

What does Editas Medicine do?

Editas Medicine Inc. is a rising biopharmaceutical company specializing in the development of groundbreaking therapies based on genome editing. Its goal is to combat genetic diseases and other genetically related disorders by selectively modifying DNA sequences. The company was founded in 2013 by a group of renowned scientists, including prominent genome editors Jennifer Doudna and George Church. Over the years, Editas Medicine Inc. has established itself as a pioneer in the field of genome editing and has received numerous awards and funding. Its business model revolves around researching and developing innovative therapies based on genetic modifications, using approaches such as CRISPR/Cas9, TALEN, and zinc finger nucleases. The company aims to develop treatments for previously incurable, severe diseases. Its activities are divided into various business areas, including the exploration of gene therapies, the development of medications based on CRISPR/Cas9 technology, and the research of genome-based diagnostic options. Editas Medicine Inc. has already introduced some products to the market or is in advanced stages of development, such as the medication LCA10 for a rare form of blindness and the medication CEP290 for a severe genetic disease. Overall, Editas Medicine Inc. has experienced remarkable growth in recent years, becoming one of the key players in genome editing. The market for gene therapies and genome-based treatments has significant growth potential, making the company's prospects promising. Editas Medicine Inc. is dedicated to advancing genomic medicine by developing groundbreaking solutions for incurable diseases and providing a platform for new technologies in the market. Editas Medicine ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Editas Medicine's P/E Ratio

The Price to Earnings (P/E) Ratio of Editas Medicine is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Editas Medicine's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Editas Medicine is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Editas Medicine’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Editas Medicine Stock

What is the price-to-earnings ratio of Editas Medicine?

The price-earnings ratio of Editas Medicine is currently -1.84.

How has the price-earnings ratio of Editas Medicine changed compared to last year?

The price-to-earnings ratio of Editas Medicine has increased by -61.1% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Editas Medicine high compared to other companies?

Yes, the price-to-earnings ratio of Editas Medicine is high compared to other companies.

How does an increase in the price-earnings ratio of Editas Medicine affect the company?

An increase in the price-earnings ratio of Editas Medicine would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Editas Medicine affect the company?

A decrease in the price-earnings ratio of Editas Medicine would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Editas Medicine?

Some factors that influence the price-earnings ratio of Editas Medicine are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Editas Medicine pay?

Over the past 12 months, Editas Medicine paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Editas Medicine is expected to pay a dividend of 0 USD.

What is the dividend yield of Editas Medicine?

The current dividend yield of Editas Medicine is .

When does Editas Medicine pay dividends?

Editas Medicine pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Editas Medicine?

Editas Medicine paid dividends every year for the past 0 years.

What is the dividend of Editas Medicine?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Editas Medicine located?

Editas Medicine is assigned to the 'Health' sector.

Wann musste ich die Aktien von Editas Medicine kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Editas Medicine from 4/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/30/2024.

When did Editas Medicine pay the last dividend?

The last dividend was paid out on 4/30/2024.

What was the dividend of Editas Medicine in the year 2023?

In the year 2023, Editas Medicine distributed 0 USD as dividends.

In which currency does Editas Medicine pay out the dividend?

The dividends of Editas Medicine are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The Editas Medicine stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von Editas Medicine

Our stock analysis for Editas Medicine Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Editas Medicine Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.